Turn Therapeutics’ (TTRX) Buy Rating Reiterated at D. Boral Capital

Turn Therapeutics (NASDAQ:TTRX)‘s stock had its “buy” rating reiterated by equities researchers at D. Boral Capital in a note issued to investors on Tuesday,Benzinga reports. They presently have a $8.00 target price on the stock. D. Boral Capital’s price objective suggests a potential upside of 75.44% from the stock’s current price.

Several other research analysts also recently weighed in on TTRX. Weiss Ratings assumed coverage on Turn Therapeutics in a research note on Monday, January 5th. They issued a “sell (e-)” rating on the stock. D Boral Capital raised Turn Therapeutics to a “strong-buy” rating in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Turn Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $8.00.

Turn Therapeutics Trading Down 5.4%

NASDAQ TTRX opened at $4.56 on Tuesday. The company has a fifty day simple moving average of $3.70. Turn Therapeutics has a one year low of $2.57 and a one year high of $26.50. The firm has a market capitalization of $134.25 million and a price-to-earnings ratio of -65.14.

Turn Therapeutics (NASDAQ:TTRX) last announced its earnings results on Thursday, November 13th. The company reported ($0.07) earnings per share for the quarter.

Insider Activity at Turn Therapeutics

In other Turn Therapeutics news, insider Abraham Chesed bought 14,286 shares of the company’s stock in a transaction on Thursday, October 23rd. The shares were bought at an average price of $4.60 per share, for a total transaction of $65,715.60. Following the transaction, the insider owned 1,447,268 shares of the company’s stock, valued at approximately $6,657,432.80. This trade represents a 1.00% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Arthur F. Golden bought 20,532 shares of the business’s stock in a transaction dated Friday, November 21st. The shares were acquired at an average cost of $2.87 per share, with a total value of $58,926.84. Following the completion of the purchase, the director owned 50,734 shares in the company, valued at approximately $145,606.58. This represents a 67.98% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have acquired a total of 52,136 shares of company stock worth $183,463 in the last quarter.

Hedge Funds Weigh In On Turn Therapeutics

An institutional investor recently bought a new position in Turn Therapeutics stock. RVW Wealth LLC purchased a new stake in Turn Therapeutics Inc. (NASDAQ:TTRX) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 18,000 shares of the company’s stock, valued at approximately $71,000. RVW Wealth LLC owned approximately 0.06% of Turn Therapeutics as of its most recent SEC filing.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.